Profile data is unavailable for this security.
About the company
ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.
- Revenue in GBP (TTM)69.96k
- Net income in GBP-2.99m
- Incorporated2000
- Employees13.00
- LocationImmuPharma PLCOne Bartholomew CloseLONDON EC1A 7BLUnited KingdomGBR
- Phone+44 20 7152 4080Fax+44 20 7152 4001
- Websitehttps://www.immupharma.co.uk/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
ValiRx Plc | 0.00 | -2.41m |
BSF Enterprise PLC | 12.94k | -1.50m |
Cizzle Biotechnology Holdings PLC | 0.00 | -953.00k |
Genflow Biosciences PLC | 0.00 | -1.18m |
ImmuPharma PLC | 69.96k | -2.99m |
Cambridge Nutritional Sciences PLC | 9.05m | -3.21m |
Bivictrix Therapeutics PLC | 0.00 | -2.33m |
Proteome Sciences plc | 5.03m | -2.44m |
Chill Brands Group PLC | 146.62k | -3.64m |
Kanabo Group PLC | 813.00k | -4.66m |
Abingdon Health PLC | 5.34m | -2.24m |
Synairgen plc | 0.00 | -9.99m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
KW Investment Management Ltd.as of 01 Mar 2024 | 71.29m | 17.12% |
Hargreaves Lansdown Asset Management Ltd.as of 01 Mar 2024 | 20.40m | 4.90% |
Chelverton Asset Management Ltd.as of 30 Jun 2023 | 15.00m | 3.60% |
HSBC Global Asset Management (UK) Ltd.as of 01 Mar 2024 | 11.10m | 2.67% |
IG Markets Ltd.as of 01 Mar 2024 | 10.54m | 2.53% |
Bank J. Safra Sarasin AG (Investment Management)as of 01 Mar 2024 | 3.26m | 0.78% |
HSBC Bank Plc (Market-Maker)as of 01 Mar 2024 | 2.56m | 0.62% |
Jarvis Investment Management Ltd.as of 01 Mar 2024 | 2.44m | 0.59% |
Close Asset Management Ltd.as of 01 Mar 2024 | 2.24m | 0.54% |
Aviva Investors Global Services Ltd.as of 20 Apr 2018 | 2.09m | 0.50% |